Flash FinanceUS
Market closed S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · BioMarin Pharmaceutical (BMRN)

BioMarin Q4 revenue rises 17% to $875 million; GAAP net loss follows ROCTAVIAN charges

Mixed Impact 4 of 5 earnings Written later

BioMarin reported fourth-quarter 2025 revenue of $875 million, up 17% from a year earlier, but swung to a GAAP net loss of $47 million after about $240 million in charges tied to its decision to withdraw ROCTAVIAN from the market. The company guided 2026 total revenue to $3.325 billion to $3.425 billion and non-GAAP diluted EPS to $4.95 to $5.15, excluding the pending Amicus Therapeutics acquisition, which is expected to close in the second quarter of 2026.

Key points

  • Q4 2025 total revenue was $875 million, up 17%; VOXZOGO revenue rose 31% to $273 million.
  • Q4 2025 GAAP net loss was $47 million, or $(0.24) per diluted share, compared with net income of $125 million in Q4 2024.
  • 2026 guidance: total revenue of $3.325 billion to $3.425 billion and non-GAAP diluted EPS of $4.95 to $5.15, versus $3.15 for 2025.
  • Full-year 2025 GAAP diluted EPS was $1.80, down from $2.21 in 2024; guidance excludes any contribution from Amicus, expected to close in Q2 2026.

The filing

CompanyBioMarin Pharmaceutical (BMRN)
Form8-K, current report
Filed with the SECFeb 23, 2026, 4:08 PM ET
Accession number0001048477-26-000002

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 12:56 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 23, 2026.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.